Adipocyte dysfunction is strongly associated with the development of obesity, which is a major risk factor for many disorders including diabetes, hypertension, and heart disease. It is generally accepted that the regulation of adipogenesis or adipokines expression prevents obesity. In this study, we show that isorhamnetin inhibits adipocyte differentiation, as evidenced by reduced triglyceride (TG) accumulation and glycerol‐3‐phosphate dehydrogenase (GPDH) activity. At the molecular level, the mRNA expression levels of peroxidase proliferator‐activated receptor‐γ (PPAR‐γ) and CCAAT/enhancer‐binding protein‐α (C/EBP‐α), which are the major adipogenic transcription factors, were markedly reduced by isorhamnetin. However, the mRNA levels of C/EBP‐β and ‐δ, the upstream regulators of PPAR‐γ and C/EBP‐α, were not reduced by isorhamnetin. Moreover, the mRNA levels of PPAR‐γ target genes such as lipoprotein lipase (LPL), CD36, aP2, and liver X receptor‐α (LXR‐α) were downregulated by isorhamnetin. We also showed that isorhamnetin inhibits the expression and secretion of adiponectin, and the results of adiponectin promoter assays suggest the inhibition of PPAR‐γ expression as a possible mechanism underlying the isorhamnetin‐mediated effects. Taken together, these results indicate that isorhamnetin inhibits adipogenesis through downregulation of PPAR‐γ and C/EBP‐α.